Biological Information
Background Information:
Src family tyrosine kinases are nonreceptor tyrosine kinases that are functionally linked to some receptor-type tyrosine kinases, G-protein-coupled receptors, cytokine receptors, and cell adhesion molecules/receptors. Src family tyrosine kinases are membrane-associated proteins having Src homology 2 (SH2) and SH3 domains, which are important for protein-protein interaction. The activity of Src family tyrosine kinases is regulated through intramolecular interaction between the SH2 domain and the phosphorylated tyrosine at the C-terminal regulatory site (Tyr-527).
Family:
Kinase
Sub Family:
TK
Class:
Protein Tyrosine
Protein Name:
Src
Uniprot Number:
P12931
Protein Aliases:
Proto-oncogene c-Src|pp60c-src|p60-Src
Gene Name:
SRC
Gene ID:
6714
Gene Aliases:
ASV|c-src
Accession Number:
NM_005417
Organism:
Human
Construct Details:
Full Length, Recombinant
Assay Information
Assay Type:
Biochemical
Assay Sub Type:
Enzymatic
Functional Mode:
Antagonist
Detection Method:
Radiometry
Measured Response:
Scintillation
Testing Information
Procedure Summary:
Human recombinant protein kinase SRC expressed in insect cells is used. Test compound and/or vehicle is preincubated with 0.023 μg/ml enzyme‡ in modified HEPES buffer pH 7.4 for 15 minutes at 37°C. The reaction is initiated by addition of 0.2 mg/ml poly(Glu:Tyr), 10 μM ATP and 0.05 μCi [γ³²P]ATP for another 30 minute incubation period and terminated by further addition of 3% H3PO4. An aliquot is removed and counted to determine the amount of [³²P]Poly(Glu:Tyr) formed. Compounds are screened at 10 μM.
Substrate:
200 µg/ml Poly(Glu:Tyr)
ATP Concentration:
10 uM
Incubation:
30 min at 37°C
Control Inhibitor:
Staurosporine
Criteria For Significance:
≥ 50% of max stimulation or inhibition
Test Concentration / Dose:
Suggested concentration for initial testing is 10 uM
Test Sample Requirements:
Minimum for 1) Screen: 25 μl of 10 mM stock -OR- 1 mg (pre-weighed). 2) Dose Response: 60 μl of 10 mM stock -OR- 1 mg (pre-weighed).
Minimum Order Quantity:
10
Turnaround Time
Standard:
15 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology
Adverse / Beneficial Action:
Inhibition of SRC (p60-Src, c-src) may be useful in the treatment of breast and colon carcinoma.
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei